Browse NFAT5

Summary
SymbolNFAT5
Namenuclear factor of activated T-cells 5, tonicity-responsive
Aliases TONEBP; KIAA0827; NFATL1; OREBP; NFATZ; NF-AT5; NFAT-like protein 1; T-cell transcription factor NFAT5; TonE ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Note=Nuclear distribution increases under hypertonic conditions.
Domain PF16179 Rel homology dimerisation domain
PF00554 Rel homology DNA-binding domain
Function

Transcription factor involved, among others, in the transcriptional regulation of osmoprotective and inflammatory genes. Mediates the transcriptional response to hypertonicity (PubMed:10051678). Positively regulates the transcription of LCN2 and S100A4 genes; optimal transactivation of these genes requires the presence of DDX5/DDX17 (PubMed:22266867). Binds the DNA consensus sequence 5'-[ACT][AG]TGGAAA[CAT]A[TA][ATC][CA][ATG][GT][GAC][CG][CT]-3' (PubMed:10377394).

> Gene Ontology
 
Biological Process GO:0006970 response to osmotic stress
GO:0007588 excretion
GO:0019722 calcium-mediated signaling
GO:0019932 second-messenger-mediated signaling
GO:0033173 calcineurin-NFAT signaling cascade
GO:0048016 inositol phosphate-mediated signaling
GO:0050848 regulation of calcium-mediated signaling
GO:0070884 regulation of calcineurin-NFAT signaling cascade
GO:0097720 calcineurin-mediated signaling
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolNFAT5
Namenuclear factor of activated T-cells 5, tonicity-responsive
Aliases TONEBP; KIAA0827; NFATL1; OREBP; NFATZ; NF-AT5; NFAT-like protein 1; T-cell transcription factor NFAT5; TonE ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NFAT5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolNFAT5
Namenuclear factor of activated T-cells 5, tonicity-responsive
Aliases TONEBP; KIAA0827; NFATL1; OREBP; NFATZ; NF-AT5; NFAT-like protein 1; T-cell transcription factor NFAT5; TonE ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NFAT5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNFAT5
Namenuclear factor of activated T-cells 5, tonicity-responsive
Aliases TONEBP; KIAA0827; NFATL1; OREBP; NFATZ; NF-AT5; NFAT-like protein 1; T-cell transcription factor NFAT5; TonE ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NFAT5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2080.484
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1740.894
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2430.762
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0450.914
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3170.906
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3010.932
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0940.815
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0370.984
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1810.925
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0780.929
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8380.459
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2040.0349
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NFAT5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolNFAT5
Namenuclear factor of activated T-cells 5, tonicity-responsive
Aliases TONEBP; KIAA0827; NFATL1; OREBP; NFATZ; NF-AT5; NFAT-like protein 1; T-cell transcription factor NFAT5; TonE ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NFAT5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNFAT5
Namenuclear factor of activated T-cells 5, tonicity-responsive
Aliases TONEBP; KIAA0827; NFATL1; OREBP; NFATZ; NF-AT5; NFAT-like protein 1; T-cell transcription factor NFAT5; TonE ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NFAT5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NFAT5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNFAT5
Namenuclear factor of activated T-cells 5, tonicity-responsive
Aliases TONEBP; KIAA0827; NFATL1; OREBP; NFATZ; NF-AT5; NFAT-like protein 1; T-cell transcription factor NFAT5; TonE ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NFAT5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNFAT5
Namenuclear factor of activated T-cells 5, tonicity-responsive
Aliases TONEBP; KIAA0827; NFATL1; OREBP; NFATZ; NF-AT5; NFAT-like protein 1; T-cell transcription factor NFAT5; TonE ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NFAT5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNFAT5
Namenuclear factor of activated T-cells 5, tonicity-responsive
Aliases TONEBP; KIAA0827; NFATL1; OREBP; NFATZ; NF-AT5; NFAT-like protein 1; T-cell transcription factor NFAT5; TonE ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NFAT5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNFAT5
Namenuclear factor of activated T-cells 5, tonicity-responsive
Aliases TONEBP; KIAA0827; NFATL1; OREBP; NFATZ; NF-AT5; NFAT-like protein 1; T-cell transcription factor NFAT5; TonE ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NFAT5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.